大麻与泌尿科患者的下尿路症状及疼痛
本文通过检索PubMed截至2019年1月的相关研究,评估大麻素在泌尿系统症状中的临床作用。对癌性疼痛,高级别研究显示耐受性好但获益不明确。结论认为大麻素短期耐受性良好,但对泌尿系统不适的疗效和长期影响尚未证实,需进一步开展精心设计的随机对照试验。
要点
- 大麻素对神经源性下尿路症状疗效不一,对非神经源性下尿路症状证据不足。
- 对癌性疼痛,大麻素耐受性好但获益不明确;对非癌性疼痛和围手术期疼痛证据有限。
- 大麻素短期耐受性良好,但长期影响未知,需随机对照试验进一步探索。
核心结论
- 大麻素在泌尿系统不适中的疗效和长期影响尚未证实,需进一步开展精心设计的随机对照试验。
主要发现
- 大麻素对神经源性下尿路症状疗效不一,对非神经源性下尿路症状证据很少。
- 对慢性非癌性疼痛和围手术期疼痛证据很少。
- 对癌性疼痛,高级别研究显示大麻素耐受性良好但获益不明确。
临床怎么用
- 临床应告知患者大麻素短期耐受性良好,但对泌尿系统症状的疗效和长期影响尚未证实。
局限性
- 证据质量有限,缺乏精心设计的随机对照试验,长期影响未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe marijuana's clinical role for urologic symptoms. METHODS: Studies related to marijuana, voiding dysfunction, lower urinary tract symptoms (LUTS), and pain through January 2019 from PubMed were evaluated for relevance and quality. RESULTS: Forty-eight studies were reviewed. Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non-cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit. CONCLUSION: Cannabinoids appear well-tolerated in the short-term, but their efficacy and long-term impact is unproven and unknown in urologic discomfort. Cannabinoids for urologic symptoms should be further explored with well-designed randomized controlled trials.
引用
- Pham MN, Hudnall MT, Nadler RB, et al. Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient. Urology. 2020. PMID: 32027882. doi:10.1016/j.urology.2020.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。